We are monitoring the impact of COVID-19 on Europe Migraine Drug Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 3952
Share on
Share on

Europe Migraine Drugs Market Research Report - Segmented By Treatment, Therapeutic Class & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis, Size, Share, Trends and Growth Forecast (2020 to 2025)

Pulished: February, 2020
ID: 3952
Pages: 148

Europe Migraine Drugs Market Size (2020 to 2025)

The size of the Europe Migraine Drugs Market is estimated to worth USD 1.17 billion in 2020 and estimated to be growing at a CAGR of 4.44 % to reach USD 1.46 billion by 2025. Migraines are a source of both lost productivity and medical costs. The European market is the second-largest migraine drug market in the world. Growing patient population and escalating awareness among the patients relevant to the control and treatment of migraine are accelerating the market growth. UK, Germany, and France are the major contributors to the European region's migraine drug market.

The growing aging population and rising incidence rate of migraine in Europe are majorly driving the migraine market in Europe during the forecast period. Enhancements in the reimbursement policies associated with the medications and increasing awareness in people by organizing programs are favorable factors to the market growth. The unmet needs and growing R&D investments are further expected to support the market during the forecast period.

High investments required for the R&D for the drug discovery and strict regulations made by the governments towards the migraine headache are the restraining factors the market growth. Repercussions associated with the usage of migraine drugs may restrict market growth during the analysis period.

This research report on the European Migraine Drugs Market has been segmented and sub-segmented into the following categories:

By Treatment:

  • Preventive
  • Absorptive

By Therapeutic Class:

  • Triptants
  • Ergots
  • Others

By Country: 

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Regionally, the UK's migraine drug market is expected to lead the European market due to the growing patient population, changes in lifestyle, rising endorsement of new drug classes, and the invention of peptide-based therapies for the medication of migraine. Around 900,000 adults in the UK are suffering from chronic migraines. The market key players operating in the UK market are coming with the product and new drug launches and strategic collaborations to toughen their market status.  

The Germany Migraine Drugs Market is expected to hike at a favorable CAGR from 2020 to 2025. Approval of the new drugs manufactured to treat migraine headaches, the presence of key players like Pfizer, Eli Lilly, and many more are driving the market. Moreover, the FDA approvals of novel drugs by the key players in the market accelerate the region's growth.

France and Italy are expected to have strong growth in the upcoming years. High uncovering to screens and pressurized lifestyle, and the existence of product pipeline are to provide support to the market in having robust growth over the upcoming years.

Key players operating in the Europe Migraine Drugs Market profiled in this report are Allergan, GlaxoSmithKline, Pfizer, Endo, Impax Laboratories. The other prominent vendors the market include AbbottAeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, Bayer, CoLucid, Eli Lilly, IntelGenx, Ethypharm, Johnson & Johnson, Kowa Pharmaceuticals America, Klaria, Luitpold Pharmaceuticals, AstraZeneca, Meda, Dr. Reddy's Laboratories, OptiNose, Pfizer, Pozen, Eisai, Raptor, RedHill, SUDA, Teva, Aegis Therapeutics, Merck, TG Therapeutics, NValeant, Winston Pharmaceuticals, Allergan, and Zogenix.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods    

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Treatment                  

                                5.1.1 Introduction           

                                5.1.2 Preventive              

                                5.1.3 Abortive   

                                5.1.4  Y-o-Y Growth Analysis, By Treatment         

                                5.1.5  Market Attractiveness Analysis, By Treatment       

                                5.1.6  Market Share Analysis, By Treatment        

                5.2 Therapeutic                

                                5.2.1 Introduction           

                                5.2.2 Triptents  

                                5.2.3 Ergots        

                                5.2.4 Others      

                                5.2.5 Y-o-Y Growth Analysis, By Therapeutic       

                                5.2.6 Market Attractiveness Analysis, By Therapeutic     

                                5.2.7 Market Share Analysis, By Therapeutic       

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Treatment

                                                6.1.3.3 By Therapeutic

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Treatment

                                                6.1.4.3 By Therapeutic

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Treatment

                                                6.1.5.3 By Therapeutic

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Allergan                       

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Endo International                  

                8.3  GlaxoSmithKline                      

                8.4 Impax                           

                8.5 Pfizer                            

                8.6 Aegis Therapeutics                  

                8.7 Alder Biopharmaceuticals                     

                8.8 Astellas                        

                8.9 AstraZeneca                               

                8.10 Aeriel BioPharma                   

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environmentGlobal Medical Aesthetics Devices Market, Medical Aesthetics Devices Market research report, Medical Aesthetics Devices industry analysis
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

 

  1. Europe Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  2. Europe Preventive Market, By Region, From 2020 to 2025 (USD Billion)
  3. Europe abortive Market, By Region, From 2020 to 2025 (USD Billion)
  4. Europe Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  5. Europe Triptents Market, By Region, From 2020 to 2025 (USD Billion)
  6. Europe Ergots Market, By Region, From 2020 to 2025 (USD Billion)
  7. Europe Others Market, By Region, From 2020 to 2025 (USD Billion)
  8. U.K. Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  9. U.K. Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  10. Germany Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  11. Germany Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  12. France Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  13. France Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  14. Italy Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  15. Italy Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  16. Spain Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  17. Spain Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample